Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia, Myelodysplastic syndrome (MDS)
Results
Phase 1
This trial looked at an immunotherapy drug called magrolimab to treat acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). Magrolimab is pronounced mah-grow-lih-mab.
The trial was for people whose AML or MDS had:
not responded to treatment (refractory) or
come back after treatment (relapsed)
The trial was open for people to join between 2015 and 2018. The team presented the results at a conference in 2018.
Recruitment start: 16 November 2015
Recruitment end: 30 June 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Paresh Vyas
Bloodwise
Experimental Cancer Medicine Centre (ECMC)
Forty Seven Inc
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
Stanford University
University of Oxford
California Institute for Regenerative Medicine (CIRM)
Last reviewed: 23 June 2024
CRUK internal database number: 12669
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
